Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
A parallel study of BFKB8488A in type 2 diabetes patients recapitulated improvements in HDL-cholesterol, triglycerides, and adiponectin, but did not demonstrate improvements in HbA1c, fasting glucose, or fasting insulin (302)
(The first was generic Byetta (exenatide), which received FDA approval just one month earlier)
Its production has ended since the semaglutide shortage was resolved by the FDA in March 2025
Rare but serious adverse effects include pancreatitis, though causality remains debated
Heidi Skolnik recognizes that while GLP-1 medications can be transformative, lasting success depends on much more than a prescription
US$ 27.89
US$ 23.73
US$ 29.18
US$ 24.20
US$ 20.61
US$ 23.21
US$ 27.18
US$ 25.28
